RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.
Status:
Not yet recruiting
Trial end date:
2030-05-01
Target enrollment:
Participant gender:
Summary
The goal of this randomized clinical trial is to compare relapse remitting multiple sclerosis
(RRMS) patients treated by ocrelizumab or by rituximab followed for 2 years. The main
question it aims to answer is : • to demonstrate the non-inferiority of rituximab versus
ocrelizumab in active relapsing MS patients on the % of patients without disease activity at
2 years.
During the 2 years, the study includes 6 follow-up visits and the completion of various
health and quality of life questionnaires. The protocol visits follow the usual schedule of
treatment infusions for the disease (at initiation of treatment, 15 days after, and then
every 6 months).
Two comparison groups: Researchers will compare rituximab treated patients versus ocrelizumab
treated patients to see the % of patients without disease activity at 2 years.